Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer

Burris, Howard A.; Yardley, Denise A.; Jones, Suzanne F.; Houston, Gerry Ann; Broome, Catherine; Thompson, Dana S.; Greco, F. Anthony; White, M.; Hainsworth, John D.

doi:10.1200/jco.2004.08.065

Cited by 97 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7A and 8A). This finding correspond well with the result that 60-70% metastatic patients with HER-2-positive tumors appear intrinsically resistant to trastuzumab as a sole therapy (30,31). Furthermore, trastuzumab alone or in combination with docetaxel or PTX was not effective in clinical trials for HER-2-positive prostate tumors (32,33).…”

Section: Discussionsupporting

confidence: 84%

Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel

Hattori

Hakoshima²,

Koga³

et al. 2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. Therapeutic agents targeting HER-2/neu have been intensively addressed over the past decades. Previously, we reported that HER-2 synthetic small interfering RNA (HER-2 siRNA) could suppress the growth of human nasopharyngeal KB tumor xenografts by intratumoral injection with lipidbased nanoparticles; however, complete regression of the tumor was not achieved. In this study, we investigated antitumor activity by RNA interference in combination with paclitaxel (PTX) for KB cells using HER-2 siRNA and HER-2 short hairpin RNA-expressing plasmid DNA (HER-2 shRNA pDNA). Suppression of HER-2 expression by siRNA or shRNA pDNA caused significant reduction of proliferation by inducing apoptosis and enhancing the sensitivity for PTX in HER-2 positive KB cells. Interestingly, an HER-2 antibody trastuzumab could not increase the antitumor effect by PTX in KB xenografts. Combination therapy by intratumoral injection of HER-2 siRNA or HER-2 shRNA pDNA with PTX significantly inhibited the tumor growth of xenografts compared with each therapy used individually. In particular, HER-2 shRNA pDNA plus PTX largely extended the mean survival days compared with HER-2 siRNA plus PTX. Collectively, these findings suggest that HER-2 shRNA-based combined therapy with PTX could be a novel strategy to inhibit the progression of HER-2-positive cancer.

show abstract

Section: Discussionsupporting

confidence: 84%

Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel

Hattori

Hakoshima²,

Koga³

et al. 2010

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…Preoperative chemotherapy for HER2-negative tumors employed one of the following regimens: AC (six cycles of doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 , q 3 weeks); dose dense (dd) AC (AC q 2 weeks with filgrastim) [11]; AD (six cycles of doxorubicin 50 mg/m 2 and docetaxel 75 mg/m 2 ) or DC (six cycles of docetaxel 75 mg/m 2 and capecitabine 2 9 dd 1,000 mg/m 2 orally during 14 days, q 3 weeks) [12,13]. For HER2-positive tumors, the regimens included ddAC and PTC (paclitaxel 80 mg/m 2 week -1 , trastuzumab 2 mg/kg and carboplatin AUC 2-3 mg/ml min times 6, q 8 weeks) after 2005 [14,15]. After one or three cycles (depending on the specific protocol) the tumor response was evaluated by contrast enhanced MRI [16].…”

Section: Clinicopathological Datamentioning

confidence: 99%

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Straver

Glas

Hannemann

et al. 2009

Breast Cancer Res Treat

226

118

View full text Add to dashboard Cite

“…Both trials confirmed that both regimens are active against MBC with tolerable side effects [166]. Other groups showed that the combination of cisplatin/carboplatin with docetaxel/paclitaxel and trastuzumab as first-line therapy in patients with MBC overexpressing HER2/neu is promising (RR up to 80%), with tolerable toxicities [167,168,169,170,171]. An added advantage in terms of RR was also noted when trastuzumab was added to the carboplatin/cisplatin and gemcitabine combination for first-line therapy of MBC patients overexpressing HER2/neu [172,173,174].…”

Section: Experience With Targeted Therapymentioning

confidence: 78%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer

Abstract: This trial confirms the activity and tolerability of weekly paclitaxel/carboplatin alone or in combination with trastuzumab in women with HER-2 overexpressing metastatic breast cancer.

Cited by 97 publications

References 17 publications

Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel

Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Contact Info

Product

Resources

About